Bionomics Limited announced that a paper describing the pharmacology of BNC375, a novel positive allosteric modulator (PAM) of the alpha 7 nicotinic acetylcholine receptor (a7 nAChR), was published online on February 24, 2020 in the peer-reviewed publication Journal of Pharmacology and Experimental Therapeutics (JPET). The paper entitled, Pharmacological characterization of the novel and selective a7 nicotinic acetylcholine receptor positive allosteric modulator BNC375, is authored by scientists from MSD and Bionomics Limited. It describes the preclinical pharmacology (cellular activity and animal-based efficacy studies) of BNC375, a compound from the Bionomics research program targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions, which was licensed to MSD in 2014. The paper presents data from a comprehensive range of pre-clinical studies performed with BNC375 to explore the potential of this novel molecule to improve cognitive impairment. BNC375 enhanced long-term potentiation, a mechanism thought to underlie memory and learning, and enhanced performance in animal models testing cognition. Furthermore, the data demonstrate the potential for greater safety, selectivity, and broader effective dose range advantages of BNC375, a PAM, versus agonists or partial agonists of the a7 nAChR.